2024 marks the 75th anniversary of the founding of the People's Republic of China and the 46th anniversary of the founding of the Chinese Society of Cardiology (CSC). We are delighted to see that under the leadership of the Party, especially since the 18th National Congress of the Communist Party of China, New China has gradually moved towards prosperity and strength! China's cardiovascular disease prevention and treatment cause has the same frequency and rhythm as the development and construction of the motherland. After experiencing the initial stage, it has been passed down from generation to generation of cardiovascular doctors, and great progress has been made regardless of scale and quality. Taking the development of percutaneous coronary intervention (PCI) technology as an example, according to the report of Academician Gao Runlin (Medical Heart Network), the total number of PCI in China in 2012 was 388,883 60,000, including acute ST-segment elevation myocardial infarction (ST-segment elevation myocardial infarction, STEMI) emergency PCI more than 97,000 cases. Since then, it continued to maintain a high growth trend. By 2023, according to statistics from the Hospital Quality Monitoring System (HQMS) of the National Health Commission, the National Center for Cardiovascular Diseases announced that the total number of annual PCI cases in my country has reached 1,901,364,000, ranking the highest in the world. In particular, the number of STEMI direct PCI cases that benefit patients the most has increased from less than 100,000 cases in 2012 to more than 370,000 cases; In 2023, 128,000 STEMI patients were reported in 2,243 secondary and tertiary hospitals of the National Single Disease Quality Management and Control Platform, and their 24-h reperfusion rate (including thrombolysis and intervention) has reached 86.2%, indicating that PCI technology has saved the lives of many STEMI patients in my country.